NTRK
Augtyro Approved for Adult and Pediatric Patients With NTRK Gene Fusion-Positive Solid Tumors
The FDA has granted accelerated approval to repotrectinib (Augtyro, Bristol Myers Squibb) for adult and pediatric ...
JUNE 14, 2024
FDA Approves Vitrakvi for Solid Tumors With NTRK Gene Fusions
Larotrectinib is indicated for tumors that have a NTRK gene fusion without a known acquired resistance mutation, ...
NOVEMBER 30, 2018
Load more